Posts Archive

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma The purpose of this study is to determine the safety and efficacy of the bortezomib, lenalidomide and dexamethasone combination in patients with newly diagnosed multiple myeloma. We are looking for the highest dose of the combination that can be given safely and see how well it works as a combination in newly diagnosed patients. Sponsor: Dana-Farber Cancer Institut

SUMMIT, N.J., June 29, 2006 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has granted approval for its Supplemental New Drug Application (sNDA) for an additional indication for Revlimid (lenalidomide), for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. Two identically designed, multicenter, double-blind, phase III clinical tria

IFM 99-06 NCT00367185: Phase 3 - Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma In multiple myeloma, combination chemotherapy with melphalan plus prednisone has been used since the 1960s and is regarded as the standard of care in elderly patients. We assess whether the addition of thalidomide to this combination or adapted high-dose chemotherapy, using a melphalan 100 mg/m2 -based regimen, would improve survival. France Sponsor: University Hospital, Lille

MM-015 study NCT00405756 A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. The purpose of this study is to determine whether lenalidomide is safe and effective in the treatment of patients with newly diagnosed Multiple Myeloma who are 65 years of age or older. Sponsor Celgene Corporation Multiple Locations International Study ClinicalTrials.gov Identifier: NCT00405756 Official Title: A Phase III, Multicentre, Randomized, Double